Anonymous ID: 7c06ea Oct. 5, 2021, 5:54 p.m. No.98687   ๐Ÿ—„๏ธ.is ๐Ÿ”—kun   >>8745

Rasta Redpill

@RastaRedpill

 

Herschel Walkerโ€™s son Christian Walker, who has paid $70,000 for remote classes, was told to upload his vaccination status or his classes will be dropped - WTF

 

https://twitter.com/RastaRedpill/status/1445522029831024641

Anonymous ID: 7c06ea Oct. 5, 2021, 6:07 p.m. No.98697   ๐Ÿ—„๏ธ.is ๐Ÿ”—kun

Christopher F. Rufo Crossed swords

@realchrisrufo

ยท Oct 4

BREAKING: Attorney General Merrick Garland has instructed the FBI to mobilize against parents who oppose critical race theory in public schools, citing "threats."

 

The letter follows the National School Board Association's request to classify protests as "domestic terrorism."

 

https://twitter.com/realchrisrufo/status/1445167453105897475

Anonymous ID: 7c06ea Oct. 5, 2021, 6:11 p.m. No.98702   ๐Ÿ—„๏ธ.is ๐Ÿ”—kun   >>8745

https://t.me/KanekoaTheGreat/1981

 

Quotes from BioNTech's SEC Filing To Investors (Feb 2020)

 

"Our investors currently include... the Bill & Melinda Gates Foundation."

 

"On August 30, 2019, we entered into a letter agreement and an investment agreement with the Bill & Melinda Gates Foundation, or BMGF, pursuant to which BMGF acquired 3,038,674 of our ordinary shares for $55 million at the price of our Series B financing."

 

First case of COVID-19 dates back to November 17, 2019 according to South China Morning Post and there are reports of a potential outbreak during the October 18-27, 2019 Military Games in Wuhan, China.

 

To summarize, Gates invested $55 million in BioNTech 1.5 - 2.5 months before the first COVID-19 cases.

 

October 1, 2021: BioNTech (BNTX) $254.79 per share

3,038,674 shares x $254.79 = $774,223,748.46

$774,223,748.46 - $55,000,000 = $719,223,748.46

 

Since August 30, 2019, Gates made $719 million in profit on his $55 million BioNTech investment.

 

"We are a clinical-stage biopharmaceutical company with no pharmaceutical products approved for commercial sale."

 

"No mRNA immunotherapy has been approved, and none may ever be approved, in this new potential category of therapeutics. mRNA drug development has substantial clinical development and regulatory risks due to the novel and unprecedented nature of this new category of therapeutics."

 

"To our knowledge, there is no current precedent for an mRNA-based immunotherapy such as the type we are developing being approved for sale by the FDA, European Commission or any other regulatory agency elsewhere in the world."

 

https://www.sec.gov/Archives/edgar/data/1776985/000119312520022991/d838504df1.htm

 

NOTHING AT ALL SUSPICIOUS HERE